-transparent.png){kind=logo}
In several diseases, such as disseminated intravascular coagulation, fibrin-fibrinogen degradation products (FDP) can be detected when serum is used. To avoid the use of serum with the risk of falsely positive and negative results, and to quantitatively measure routinely low levels of FDP in plasma, we developed a solid-phase enzyme immunoassay (EIA), using a monoclonal antibody (No. FDP-14). It reacts specifically with FDP, but not with the parent fibrinogen-fibrin molecule. To raise the monoclonal antibodies we injected into mice a whole mixture of fibrin degradation products isolated after complete lysis of a human blood clot by tissue-type plasminogen activator, because there is a chance that such products resemble FDP in patients' blood more closely than antigens derived from purified fibrinogen. The EIA developed is a two-step assay ("cap-tag procedure"), in which the monoclonal antibody is attached to the wells of microtiter plates. The monoclonal antibody is specific for a neoantigenic determinant in the fragment E moiety, exposed after degradation of fibrinogen-fibrin by plasmin. The assay discriminates neither between degradation products of fibrinogen and fibrin nor between fibrin degradation products that are or are not cross-linked. It is not disturbed by the presence of fibrinogen or fibrin monomer in plasma. The assay is accurate above 60 ng FDP per milliliter and has a detection limit down to approximately 10 ng FDP per milliliter when the supernatant of a lysed blood clot is used as calibration material. In frozen, then thawed plasma specimens from normal individuals, FDP values varied between 30 and 110 ng/ml. Plasma of patients with disseminated intravascular coagulation and of patients receiving thrombolytic therapy had increased FDP values. In patients with ovarian carcinoma, FDP concentrations in plasma varied with the clinical course of the disease. Results indicate that the EIA for FDP in plasma is promising as a diagnostic tool in different clinical situations.
J Koopman, and
F Haverkate, and
P Koppert, and
W Nieuwenhuizen, and
E J Brommer, and
W G Van der Werf
December 1986,
Thrombosis research,
J Koopman, and
F Haverkate, and
P Koppert, and
W Nieuwenhuizen, and
E J Brommer, and
W G Van der Werf
April 1988,
Thrombosis and haemostasis,
J Koopman, and
F Haverkate, and
P Koppert, and
W Nieuwenhuizen, and
E J Brommer, and
W G Van der Werf
January 1975,
Texas reports on biology and medicine,
J Koopman, and
F Haverkate, and
P Koppert, and
W Nieuwenhuizen, and
E J Brommer, and
W G Van der Werf
January 1990,
Haemostasis,
J Koopman, and
F Haverkate, and
P Koppert, and
W Nieuwenhuizen, and
E J Brommer, and
W G Van der Werf
September 1985,
Clinical chemistry,
J Koopman, and
F Haverkate, and
P Koppert, and
W Nieuwenhuizen, and
E J Brommer, and
W G Van der Werf
May 1987,
Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society,
J Koopman, and
F Haverkate, and
P Koppert, and
W Nieuwenhuizen, and
E J Brommer, and
W G Van der Werf
February 1985,
Thrombosis and haemostasis,
J Koopman, and
F Haverkate, and
P Koppert, and
W Nieuwenhuizen, and
E J Brommer, and
W G Van der Werf
August 1983,
Thrombosis and haemostasis,
J Koopman, and
F Haverkate, and
P Koppert, and
W Nieuwenhuizen, and
E J Brommer, and
W G Van der Werf
December 1993,
Rinsho byori. The Japanese journal of clinical pathology,
J Koopman, and
F Haverkate, and
P Koppert, and
W Nieuwenhuizen, and
E J Brommer, and
W G Van der Werf
March 1991,
The Journal of steroid biochemistry and molecular biology,
